Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Ventricular Tachycardia Ablation Guidance Includes Randomized Studies

This article was originally published in The Gray Sheet

Executive Summary

Randomized clinical studies remain an option for sponsors seeking approval of ablation devices for the treatment of ventricular tachycardia (VT), FDA's Center for Devices and Radiological Health says in a recent guidance.

You may also be interested in...

Randomized Controlled Trials May Be Less Burdensome, FDA Guidance Says

Randomized controlled clinical trials of medical devices represent, in certain circumstances, the least burdensome route for sponsors to gain FDA approval, the agency maintains.

US FDA Not Changing Assessment Goals Because of Coronavirus-Mandated Telework

Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts